Compare Endeavour Silver Corp (EXK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Viatris Inc — how do they compare? Endeavour Silver Corp trades at $7.47 (market cap $2.36B), while Viatris Inc trades at $17.27 (market cap $19.44B). The key difference: Viatris Inc is far larger — about 8.2× Endeavour Silver Corp's market cap, and Viatris Inc pays a 2.88% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | VTRS | |
|---|---|---|
Market Cap | $2.36B | $19.44B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $17.39 |
52-Week Low | $4.96 | $8.74 |
Enterprise Value | $2.36B | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $7.47, down 7.55% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 production of 3.4 million silver equivalent ounces and beat Q1 2026 earnings estimates with $0.21 EPS versus $0.10 expected. Despite negative net income margins and ROE, revenue growth is projected to improve from $468M in 2025 to $614M in 2026. Analyst sentiment remains positive with 78.57% buy ratings.
The outlook is mixed: operational momentum and silver price trends offer upside, but profitability challenges and high valuation ratios pose risks. Investors should weigh strong production growth against persistent negative earnings and cash flow concerns in a volatile commodity market.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
